| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Tanox Pharma B.V., Amsterdam, The Netherlands;
Department of Immunobiology, Biomedical Primate Research Center, Rijswijk, The Netherlands;
Department of Neuroimmunology, Institute of Brain Research, University of Vienna, Vienna, Austria;
Division of Immunological and Infectious Diseases, Netherlands Central Organization for Applied Scientific Research Prevention and Health, Leiden, The Netherlands;
¶ Imaging Science Institute, University Medical Center, Utrecht, The Netherlands;
||
Division of Experimental Immunology, Faculty of Medicine, Catholic University of Leuven, Belgium;
#
Department of Immunology, Erasmus University, Rotterdam, The Netherlands; and
**
Academic Hospital Dijkzigt, Dijkzigt, The Netherlands
Inhibition of CD40-CD40 ligand interaction is a potentially effective approach for treatment of autoimmune diseases, such as multiple sclerosis. We have investigated this concept with a chimeric antagonist anti-human CD40 mAb (ch5D12) in the marmoset monkey experimental autoimmune encephalomyelitis (EAE) model. Marmosets were immunized with recombinant human myelin oligodendrocyte glycoprotein (rMOG) and treated from the day before immunization (day -1) until day 50 with either ch5D12 (5 mg/kg every 2–4 days) or placebo. On day 41 after the induction of EAE, four of four placebo-treated monkeys had developed severe clinical EAE, whereas all animals from the ch5D12-treated group were completely free of disease symptoms. High serum levels of ch5D12 associated with complete coating of CD40 on circulating B cells were found. At necropsy placebo- and ch5D12-treated animals showed similar MOG-specific lymphoproliferative responses in vitro, but ch5D12 treatment resulted in strongly reduced anti-MOG IgM Ab responses and delayed anti-MOG IgG responses. Most importantly, treatment with ch5D12 prevented intramolecular spreading of epitope recognition. Postmortem magnetic resonance imaging and immunohistologic analysis of the CNS showed a markedly reduced lesion load after ch5D12 treatment. In conclusion, the strong reduction of clinical, pathological, and radiological aspects of EAE by ch5D12 treatment in this preclinical model points to a therapeutic potential of this engineered antagonist anti-CD40 mAb for multiple sclerosis.
This article has been cited by other articles:
|
|
 |
|
  Y. S. Kap, M. van Meurs, N. van Driel, G. Koopman, M.-J. Melief, H. P.M. Brok, J. D. Laman, and B. A. 't Hart A Monoclonal Antibody Selection for Immunohistochemical Examination of Lymphoid Tissues From Non-human Primates J. Histochem. Cytochem., December 1, 2009; 57(12): 1159 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Helliwell and A. J. Coles Monoclonal antibodies in multiple sclerosis treatment: current and future steps Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 195 - 203. [PDF]
|
|
|
|
 |
|
 Y. S. Kap, P. Smith, S. A. Jagessar, E. Remarque, E. Blezer, G. J. Strijkers, J. D. Laman, R. Q. Hintzen, J. Bauer, H. P. M. Brok, et al. Fast Progression of Recombinant Human Myelin/Oligodendrocyte Glycoprotein (MOG)-Induced Experimental Autoimmune Encephalomyelitis in Marmosets Is Associated with the Activation of MOG34-56-Specific Cytotoxic T Cells J. Immunol., February 1, 2008; 180(3): 1326 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. t Hart, H. P. M. Brok, E. Remarque, J. Benson, G. Treacy, S. Amor, R. Q. Hintzen, J. D. Laman, J. Bauer, and E. L. A. Blezer Suppression of Ongoing Disease in a Nonhuman Primate Model of Multiple Sclerosis by a Human-Anti-Human IL-12p40 Antibody J. Immunol., October 1, 2005; 175(7): 4761 - 4768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. van Beek, M. van Meurs, B. A. 't Hart, H. P. M. Brok, J. W. Neal, A. Chatagner, C. L. Harris, N. Omidvar, B. P. Morgan, J. D. Laman, et al. Decay-Accelerating Factor (CD55) Is Expressed by Neurons in Response to Chronic but Not Acute Autoimmune Central Nervous System Inflammation Associated with Complement Activation J. Immunol., February 15, 2005; 174(4): 2353 - 2365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Adams, N. Shirasugi, T. R. Jones, M. M. Durham, E. A. Strobert, S. Cowan, P. Rees, R. Hendrix, K. Price, N. S. Kenyon, et al. Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival J. Immunol., January 1, 2005; 174(1): 542 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Zuhlke and G. Weinbauer The Common Marmoset (Callithrix jacchus) as a Model in Toxicology Toxicol Pathol, January 1, 2003; 31(1_suppl): 123 - 127. [Abstract] [PDF]
|
|
|
|
|
|
H. P. M. Brok, M. van Meurs, E. Blezer, A. Schantz, D. Peritt, G. Treacy, J. D. Laman, J. Bauer, and B. A. 't Hart Prevention of Experimental Autoimmune Encephalomyelitis in Common Marmosets Using an Anti-IL-12p40 Monoclonal Antibody J. Immunol., December 1, 2002; 169(11): 6554 - 6563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. de Vos, M. van Meurs, H. P. Brok, L. A. Boven, R. Q. Hintzen, P. van der Valk, R. Ravid, S. Rensing, L. Boon, B. A. 't Hart, et al. Transfer of Central Nervous System Autoantigens and Presentation in Secondary Lymphoid Organs J. Immunol., November 15, 2002; 169(10): 5415 - 5423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Wesemann, Y. Dong, G. M. O'Keefe, V. T. Nguyen, and E. N. Benveniste Suppressor of Cytokine Signaling 1 Inhibits Cytokine Induction of CD40 Expression in Macrophages J. Immunol., September 1, 2002; 169(5): 2354 - 2360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.B. Sugerman, N.W. Savage, L.J. Walsh, Z.Z. Zhao, X.J. Zhou, A. Khan, G.J. Seymour, and M. Bigby THE PATHOGENESIS OF ORAL LICHEN PLANUS Critical Reviews in Oral Biology & Medicine, July 1, 2002; 13(4): 350 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. T. Nguyen and E. N. Benveniste Critical Role of Tumor Necrosis Factor-alpha and NF-kappa B in Interferon-gamma -induced CD40 Expression in Microglia/Macrophages J. Biol. Chem., April 12, 2002; 277(16): 13796 - 13803. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
